Alpharadin benefits prostate cancer patients in Phase II trials

09/22/2009 | Reuters

Algeta's injectable drug Alpharadin reduced pain and improved the condition of prostate cancer patients whose cancer had spread to the bone, midstage studies show. The drug is being tested in a Phase III trial, with results expected in 2011.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC